• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roundhill GLP-1 & Weight Loss ETF (NQ:OZEM)

32.38 +0.41 (+1.28%)
Official Closing Price Updated: 4:15 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,862
Open 32.44
Bid (Size) 31.00 (100)
Ask (Size) 37.25 (500)
Prev. Close 31.98
Today's Range 32.33 - 32.64
52wk Range 22.36 - 37.15
Shares Outstanding N/A
Dividend Yield 1.27%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗
Today 11:20 EDT
Via MarketBeat
News headline image
Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗
February 26, 2026
Investors are closely watching the oral GLP-1 race as competition intensifies across the sector. 
Via Stocktwits

Performance

YTD
-5.7%
-5.7%
1 Month
+5.1%
+5.1%
3 Month
-10.5%
-10.5%
6 Month
+16.5%
+16.5%
1 Year
+42.2%
+42.2%

More News

Read More
News headline image
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗
February 25, 2026
Via Stocktwits
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗
February 12, 2026
Via Stocktwits
News headline image
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗
February 10, 2026
Via Stocktwits
Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today ↗
September 29, 2025
Via Stocktwits
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
February 05, 2026
Via Stocktwits
Topics Intellectual Property
News headline image
Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗
February 04, 2026
Via Stocktwits
Topics Intellectual Property
News headline image
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
February 04, 2026
Via Stocktwits
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
January 19, 2026
Via MarketBeat
Topics ETFs
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
October 30, 2025
Via Benzinga
Topics ETFs
News headline image
Are You Making These 3 ETF Mistakes That Cost You 50% in Gains? ↗
October 13, 2025
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat ↗
February 06, 2025
Via Stocktwits
News headline image
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish ↗
January 15, 2025
Via Stocktwits
Topics Earnings
News headline image
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections ↗
January 14, 2025
Via Stocktwits
Topics Earnings
News headline image
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗
December 13, 2024
Via Benzinga
Topics ETFs
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
July 18, 2024
Via Benzinga
News headline image
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential ↗
June 07, 2024
Via Benzinga
Topics ETFs
News headline image
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk ↗
May 30, 2024
Via Benzinga
Topics ETFs
News headline image
Tesla (TSLA) Stock Drops as Glass Lewis Urges Against Elon Musk’s Pay Package ↗
May 28, 2024
Via InvestorPlace
News headline image
Campbell Soup Layoffs 2024: What to Know About New Campbell Job Cuts ↗
May 28, 2024
Via InvestorPlace
Topics Workforce
News headline image
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF ↗
May 28, 2024
Via InvestorPlace
Topics ETFs
News headline image
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next ↗
May 23, 2024
Via Benzinga
Topics Artificial Intelligence
News headline image
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic ↗
May 21, 2024
Via Benzinga
Topics ETFs

Frequently Asked Questions

Is Roundhill GLP-1 & Weight Loss ETF publicly traded?
Yes, Roundhill GLP-1 & Weight Loss ETF is publicly traded.
What exchange does Roundhill GLP-1 & Weight Loss ETF trade on?
Roundhill GLP-1 & Weight Loss ETF trades on the Nasdaq Stock Market
What is the ticker symbol for Roundhill GLP-1 & Weight Loss ETF?
The ticker symbol for Roundhill GLP-1 & Weight Loss ETF is OZEM on the Nasdaq Stock Market
What is the current price of Roundhill GLP-1 & Weight Loss ETF?
The current price of Roundhill GLP-1 & Weight Loss ETF is 32.38
When was Roundhill GLP-1 & Weight Loss ETF last traded?
The last trade of Roundhill GLP-1 & Weight Loss ETF was at 04/17/26 04:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap